Fundamentals of Pharmacology for Veterinary Technicians Chapter 20

Size: px
Start display at page:

Download "Fundamentals of Pharmacology for Veterinary Technicians Chapter 20"

Transcription

1 Figure 20-1

2 Figure 20-2

3 Figure 20-3A

4 Figure 20-3B

5 Figure 20-4

6 Table 20-1 Antineoplastic Agents Used for Chemotherapy in Animals Drug Type Drug Category Examples Cell-Cycle Effect CCNS Alkylating agents: Cross-link DNA to inhibit its replication busulfan (Myleran, Busulfex ) carboplatin (Paraplatin ) chlorambucil (Leukeran ) cisplatin (Platinol ) cyclophosphamide (Cytoxan, Neosar ) dacarbazine (DTIC-Dome ) lomustine (CeeNu ) mechlorethamine (Mustargen ) melphalan (Alkeran ) thiotepa (Ledertepa, Tespamin ) Work on all phases of the cell cycle, but are more effective in the G 1 and Tend to be used for lymphoproliferative diseases, osteosarcoma, mast cell tumors, and carcinomas Antitumor antibiotics: Inhibit DNA, RNA, and (in some cases) protein synthesis bleomycin (Blenoxane ) dactinomycin, also known as actinomycin D (Cosmegen ) doxorubicin (Adriamycin ) mitoxantrone (Novantrone ) streptozocin (Zanosar ) Work on all phases of the cell cycle, but doxorubicin is more effective at the Tend to be used for lymphoproliferative diseases, sarcomas, and carcinomas Steroid drugs: Action may include antiinflammatory effects, suppression of bone marrow cells, reduction of edema, and suppression of tumor growth androgens (danazol [Danocrine ]) estrogens (ECP, Synovex C ) glucocorticoids (prednisone, dexamethasone) progestins (Component E-C ) Work on all phases of the cell cycle, but more effective at the S and M phases Tend to be used for lymphoproliferative diseases, reproductive cancers, mast cell tumors, and CNS tumors CCS Antimetabolites: Cell-cycle-specific drugs that affect the synthesis) azathioprine (Imuran ): antagonizes purine base metabolism 5-fluorouracil (Adrucil, 5-FU ): pyrimidine base analogs cytarabine (Cytosar-U ): pyrimidine base analog hydroxyurea (Hydrea, Droxia ): inhibits thymidine incorporation into DNA mercaptopurine (Purinethol ): antagonizes purine base metabolism methotrexate (Mexate ): inhibits folic acid synthesis thioguanine (Tabloid ): blocks purine nucleotides Work on S phase of the cell cycle. They either inhibit folic acid, which is needed for the synthesis of proteins and DNA, or by being an analog of pyrimidine or purine (which are bases occurring in DNA and RNA) and incorporating into the DNA/RNA molecule Tend to be used for lymphoproliferative Alkaloids: Chemicals derived from plants; stop cancer cell division (mitosis) vinblastine (Alkaban-AQ, Velbane ) vincristine (Oncovin, Vincasar ) Work on the M phase of the cell cycle, inhibiting mitosis and causing cell death Tend to be used for lymphoproliferative diseases, mast cell tumors, sarcomas, and carcinomas Table 20-1

7 Table 20-2 Guidelines for Handling Antineoplastic Agents Antineoplastics should be handled by trained personnel. Handling of antineoplastic agents by pregnant women is generally contraindicated. OSHA recommends that antineoplastic agents should be prepared under a vertical laminar fl ow hood (Figure 20-3). When pharmaceutical practice calls for the use of aseptic techniques and a sterile environment, a horizontal laminar flow hood is sufficient. However, while this type of unit provides product protection, it may expose the operator and the other room occupants to aerosols generated during drug preparation procedures. A vertical laminar flow hood provides both product and operator protection by fi ltering incoming and exhaust air through a high-efficiency particulate air (HEPA) filter. It is unlikely that the majority of practices will have vertical laminar flow hoods. Preparation of drugs without such equipment is a compromise on safety. In this situation, drugs should be prepared in an area away from people and animals, without doors, windows, or draughts, and the maximum possible personal protection used. This should include gloves, disposable arm sleeves and a gown, goggles, and a mask. Use latex gloves to protect the skin. Gloves made of polyvinyl chloride may be permeable to some cytotoxic agents. Wearing two pairs of latex gloves is recommended because all gloves are porous to some degree. Good handwashing before and after handling drugs is essential. Prevent contact of antineoplastic agents with skin or mucous membranes. If this occurs, wash the area immediately with large volumes of water, document the contact, and seek medical assistance. Before drug preparation, don a disposable, nonpermeable surgical gown with closed front and knit cuffs that completely cover the wrists. Goggles (or eye shield) and particulate filtration masks are recommended to avoid ocular and respiratory contact. If reconstituting the drug, vent the vial at the beginning of the procedure. Special vent needles are available and should be used. This lowers the internal pressure in the vial and reduces the risk of spilling or spraying the solution when the needle is withdrawn from the vial. Use leur-lock syringes and IV equipment that have screw-on attachments to prevent spillage of antineoplastic agents. Wipe all external surfaces of syringes and bottles with alcohol. All disposable equipment, gloves, and bottles should be placed in a separate disposable leakproof puncture-resistant plastic bag specifically marked for chemotherapy and collected for incineration. Wear latex gloves when disposing of vomit, urine, or feces from animals receiving antineoplastics. Maintain a record of all exposure during preparation, administration, cleanup, and spills. Table 20-2

8 Table 20-3 General Adverse Reactions to Antineoplastic Agents Adverse Reactions Patient Considerations Bone marrow suppression Low white blood cell counts increase the risk of infection Low platelet counts may result in bleeding Low red blood cell counts leading to anemia may cause lethargy Gastrointestinal effects Anorexia may be attributed to foul taste left in the mouth from antineoplastic agents and/or gastrointestinal upset Gastrointestinal upset and vomiting may be secondary to antineoplastic use Diarrhea may be secondary to antineoplastic use and could lead to dehydration Alopecia Infertility Hair loss varies; the animal should be kept out of the cold and should avoid excessive sunlight Infertility secondary to antineoplastic use may be permanent Cardiotoxicity Damage to the heart from certain antineoplastic drugs such as doxorubicin Nephrotoxicity Kidney failure from certain antineoplastic drugs such as cisplatin may be seen especially in animals receiving pulse dosing of medication Table 20-3

9 Table 20-4 Drugs Covered in This Chapter Category Generic Name Trade Name(s) A lkylating agents busulfan Myleran, Busulfex carboplatin Paraplatin chlorambucil Leukeran c isplatin Platinol cyclophosphamide Cytoxan, Neosar dacarbazine DTIC-Dome lomustine CeeNu mechlorethamine Mustargen melphalan Alkeran t hiotepa Ledertepa, Tespamin Antitumor antibiotics bleomycin Blenoxane dactinomycin (actinomycin D) Cosmegen doxorubicin Adriamycin mitoxantrone Novantrone streptozocin Zanosar Steroid drugs androgens (danazol) Danocrine estrogens ECP, Synovex C (Continued ) Table 20-4

10 Table 20-4 (Continued ) Category Generic Name Trade Name(s) glucocorticoids (prednisone, dexamethasone) generic, Azium progestins Component E-C Antimetabolites azathioprine Imuran 5-fluorouracil Adrucil, 5-FU cytarabine Cytosar-U hydroxyurea Hydrea, Droxia mercaptopurine Purinethol methotrexate Mexate thioguanine Tabloid A lkaloids vinblastine Alkaban-AQ vincristine Oncovin, Vincasar Biologic response modifiers interferon Roferon-A injection, Intron A injection, Alferon N injection, Actimmune injection filgrastim Neupogen sargramostim Leukine interleukin-2 Proleukin acemannan Acemannan Immunostimulant monoclonal antibodies Canine Lymphoma Monoclonal Antibody 231 Immunosuppressives cyclosporine Optimmune Ophthalmic Ointment, Sandimmune, Atopica azathioprine Imuran cyclophosphamide Cytoxan mercaptopurine Purinethol E nzyme L-asparaginase Elspar, Oncaspar, Erwinase Enzyme inhibitor Toceranib Palladia Table 20-4 continued

Medication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC

Medication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC Medication Review Cancer Chemotherapy Drugs Pharmacy Technician Training Systems Passassured, LLC Medication Review, Cancer Chemotherapy Drugs PassAssured's Pharmacy Technician Training Program Medication

More information

Antineoplastic Drugs. Antineoplastic Drugs. Herbal Alert. Pharmacology Chapter 51. Green tea

Antineoplastic Drugs. Antineoplastic Drugs. Herbal Alert. Pharmacology Chapter 51. Green tea Antineoplastic Drugs Pharmacology Chapter 51 Carolyn Wright, RN, BSN Ford, S. & Roach, S. (2010). Roach's introductory clinical pharmacology (9 th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams

More information

Hospice Skills Checklist

Hospice Skills Checklist _ XXX-XX- Print Name Last 4 of SS # Date Completed Directions Please circle a value for each question to provide us and the interested facilities with an assessment of your clinical experience. These values

More information

Oncology Skills Checklist

Oncology Skills Checklist _ XXX-XX- Print Name Last 4 of SS # Date Completed Directions Please circle a value for each question to provide us and the interested facilities with an assessment of your clinical experience. These values

More information

Introduction to Antineoplastic Prescribing

Introduction to Antineoplastic Prescribing Introduction to Antineoplastic Prescribing Robert Bradbury, R.Ph., BCPS Clinical Coordinator H. Lee Moffitt Cancer Center Objectives Meet the following goals concerning antineoplastic prescribing: Understand

More information

Exhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A

More information

REFERENCES American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006; 63:

REFERENCES American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006; 63: Ordering and Handling Applies To: UNM Hospitals Responsible Department: Pharmacy Revised: 8/2017 Procedure Patient Age Group: ( ) N/A (X) All Ages ( )Newborns ( )Pediatric ( )Adult DESCRIPTION/OVERVIEW

More information

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies: VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic

More information

To help doctors give their patients the best possible care, the American

To help doctors give their patients the best possible care, the American Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific

More information

Year III Pharm D. Dr. V. Chitra

Year III Pharm D. Dr. V. Chitra Year III Pharm D. Dr. V. Chitra 50.2 Rang Etiolopathology Cell Cycle = Growth, Division 18_01_cell_cycle.jpg Characteristics of Cancer Cells The problem: Cancer cells divide rapidly (cell cycle is accelerated)

More information

Chemotherapy and the development of novel therapeutics

Chemotherapy and the development of novel therapeutics SCPA607-Pathobiology and mechanisms of cancer Chemotherapy and the development of novel therapeutics Somphong Narkpinit, M.D. Department of Pathobiology Faculty of Science Mahidol University E-mail : somphong.nar@mahidol.ac.th

More information

2. Mitotic Spindle Inhibitors (modulators of tubulin polymerisation) 3. Antimetabolites (anti-folates, pyrimidine and purine analogues)

2. Mitotic Spindle Inhibitors (modulators of tubulin polymerisation) 3. Antimetabolites (anti-folates, pyrimidine and purine analogues) CANCER DRUG CLASSES The classes of drugs currently used in the cancer clinic are 1. DNA Binding Agents (intercalating and alkylating agents) 2. Mitotic Spindle Inhibitors (modulators of tubulin polymerisation)

More information

Cancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018

Cancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018 Cancer Chemotherapy Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018 االدوية Polyfunctional Alkylating Agents االستخالبية متعددة الوظائف Not cell cycle-specific.

More information

Cytotoxic Drugs. Table of Contents

Cytotoxic Drugs. Table of Contents Cytotoxic Drugs Table of Contents Introduction 3 Reasons for concern 3 Sources of exposure 4 Responsibilities for controlling exposure 5 Guidelines for controlling exposures 6 The written program 6 Preparation

More information

Cancer SLO Practice (online set) Page 1 of 5

Cancer SLO Practice (online set) Page 1 of 5 Cancer SLO Practice (online set) Page 1 of 5 1. Aranesp is? A. Darbepoetin alfa B. Filgrastim C. Epoetin alfa D. Sargramostim E. Pegfilgrastim 2. BCNU is? B. Cyclophosphamide 3. Bleomycin is a natural

More information

Cancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018

Cancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018 Cancer Chemotherapy Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018 Modalities of Cancer Chemotherapy Curative: Only in 10-15% of cases. In certain disseminated

More information

DRUGS FOR NEOPLASIA. Chapter 37

DRUGS FOR NEOPLASIA. Chapter 37 DRUGS FOR NEOPLASIA Chapter 37 Keywords- You tell Me! Cancer dz characterized by abnormal, uncontrolled cell division Tumor swelling, abnormal enlargement or mass of tissue Carcinogen any substance or

More information

Anti-cancer drugs. Introduction : Body : 1) Alkylating Agents

Anti-cancer drugs. Introduction : Body : 1) Alkylating Agents Anti-cancer drugs Introduction : In this journal I will try to explain what is anti-cancer agents, how they work, how can they inhibit the growth of tumor and what is the advantages and disadvantages of

More information

DRUGS YOU NEED TO KNOW

DRUGS YOU NEED TO KNOW jfitzake@d.umn.edu Page 1 of 7 DRUGS YOU NEED TO KNOW ALKYLATING AGENTS (blue cards) BUSULFAN CARMUSTINE (BCNU) CYCLOPHOSPHAMIDE DACARBAZINE LOMUSTINE (CCNU) MECHLORETHAMINE MELPHALAN THIOTEPA NATURAL

More information

DRUG PROPERTIES YOU NEED TO KNOW

DRUG PROPERTIES YOU NEED TO KNOW jfitzake@d.umn.edu www.d.umn.edu/~jfitzake Page 1 of 8 DRUG PROPERTIES YOU NEED TO KNOW 1. Mechanism of action a. chemical class b. resistance 2. Pharmacokinetics 3. Therapeutic uses 4. Major side effects/toxicities

More information

Antineoplastic Agents

Antineoplastic Agents 56 Antineoplastic Agents Branimir I. Sikic DRUG LIST GENERIC NAME PAGE GENERIC NAME PAGE Aldesleukin 652 Asparaginase 649 Bleomycin 647 Buserelin 650 Busulfan 642 Carboplatin 652 Carmustine 641 Chlorambucil

More information

Acute Lymphocytic Leukemia

Acute Lymphocytic Leukemia Acute Lymphocytic Leukemia Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Alemtuzumab (Campath ) Arsenic Trioxide (Trisenox ) Bendamustine (Treanda ) Bexarotene (Targretin ) Bleomycin

More information

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric

More information

Chapter 37. Media Directory. Tumor (neoplasm) Cancer (carcinoma) Causes of Cancer. Drugs for Neoplasia

Chapter 37. Media Directory. Tumor (neoplasm) Cancer (carcinoma) Causes of Cancer. Drugs for Neoplasia Chapter 37 Media Directory Drugs for Neoplasia Slide 39 Slide 41 Cyclophosphamide Animation Methotrexate Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cancer (carcinoma) Tumor (neoplasm)

More information

Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and

Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and 35 Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and Biologically directed therapies ) 1 1- Nausea and vomiting

More information

CHEMOTHERAPY/ ANTICANCER DRUGS/ NEOPLASTIC AGENTS

CHEMOTHERAPY/ ANTICANCER DRUGS/ NEOPLASTIC AGENTS CHEMOTHERAPY/ 1 Oncology, Misc, Vaccines ANTICANCER DRUGS/ NEOPLASTIC AGENTS Important Terms: Cancer: A group of diseases involving abnormal cell growth with the potential to invade or spread to other

More information

DRUG EXTRAVASATION. Vesicants. Irritants

DRUG EXTRAVASATION. Vesicants. Irritants DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)

More information

Chemotherapy and biotherapy: guidelines and recommendations for practice.

Chemotherapy and biotherapy: guidelines and recommendations for practice. Complete Summary GUIDELINE TITLE Chemotherapy and biotherapy: guidelines and recommendations for practice. BIBLIOGRAPHIC SOURCE(S) Oncology Nursing Society (ONS). Chemotherapy and biotherapy: guidelines

More information

Lecture 2: DNA cross-linkers and alkylating agents regarded as non-cell cycle specific

Lecture 2: DNA cross-linkers and alkylating agents regarded as non-cell cycle specific Lecture 2: DNA cross-linkers and alkylating agents regarded as non-cell cycle specific Realize that DNA is electron rich and these agents are electron poor ; hence, they react. 1. Platinum agents (we will

More information

P 1 Summary P 2 3 Part 1 General Information P 4 7 Part 2 Exposure among healthcare workers P 8 11 Part 3 Health Effects

P 1 Summary P 2 3 Part 1 General Information P 4 7 Part 2 Exposure among healthcare workers P 8 11 Part 3 Health Effects TOXICOLOGY PROFILE METHOTREXATE IN THE HEALTH CARE INDUSTRY P1Summary P23Part1GeneralInformation P47Part2Exposureamonghealthcareworkers P811Part3HealthEffects P8PulmonaryEffects P8EffectsonBone P8Hepatotoxicity

More information

Chemotherapy Teaching Points

Chemotherapy Teaching Points Chemotherapy Teaching Points 1. Antimetabolites - These drugs are analogs of vital co-factors in DNA or RNA synthesis. They competitively inhibit DNA or RNA production, or are directly incorporated into

More information

Antineoplastic Agents

Antineoplastic Agents Antineoplastic Agents Occupational Hazards in Hospitals DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational Safety and Health This document

More information

Cancer Therapeutics for Dogs and Cats

Cancer Therapeutics for Dogs and Cats Cancer Therapeutics for Dogs and Cats Alexandria Gochenauer BSPS, BA The University of Mississippi School of Pharmacy Disclosures I declare no conflicts of interest, real or apparent, and no financial

More information

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial

More information

Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007

Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Hosted by: Australian Small Animal Veterinary Association (ASAVA) Australian Small Animal Veterinary Association (ASAVA)

More information

DRUG PROPERTIES YOU NEED TO KNOW

DRUG PROPERTIES YOU NEED TO KNOW Dr. Janet Fitzakerley Summer 2013 Med 6541 Hematopoiesis and Host Defences jfitzake@d.umn.edu www.d.umn.edu/~jfitzake Page 1 of 11 DRUG PROPERTIES YOU NEED TO KNOW 1. Mechanism of action a. chemical class

More information

Cancer Incidence and Mortality

Cancer Incidence and Mortality Cancer Incidence and Mortality Cancer is a common disease. One in three people in the Western World contract cancer and one in four die from it. The cure rate is 50% Cancer is strongly age-related, the

More information

Anticancer Drugs. Cytotoxic drugs Antineoplastic agents

Anticancer Drugs. Cytotoxic drugs Antineoplastic agents Anticancer Drugs Cytotoxic drugs Antineoplastic agents 1 Principles of Cancer Chemotherapy Cancer chemotherapy strives to cause a lethal cytotoxic event or apoptosis in the cancer cells that can arrest

More information

Ovarian Cancer. compendia TREATMENT OF

Ovarian Cancer. compendia TREATMENT OF drug & compendia TREATMENT OF Ovarian Cancer With each publication, ManagedCare Oncology s drug & Compendia highlights a single medication or a group of medications that could be utilized in the management

More information

Principles of chemotherapy

Principles of chemotherapy Principles of chemotherapy Chemotherapy first coined by Paul Ehrlich Aim to selectively destroy cancer cells whilst relatively sparing tumours cells Growth characteristics of cancer cells allows for selective

More information

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET 300 Northfield Road Bedford, OH 44146 Telephone: (440) 232-3320 -or- (800) 562-4797 MATERIAL SAFETY DATA SHEET Section I - IDENTITY Common/Trade Name: Sterile Cytarabine, USP (100mg, 500mg, 1g or 2g/vial

More information

Environmental Monitoring of Cytotoxics in the Oncology Clinic: Implications for Employee Health

Environmental Monitoring of Cytotoxics in the Oncology Clinic: Implications for Employee Health Environmental Monitoring of Cytotoxics in the Oncology Clinic: Implications for Employee Health Toxicology Conference Prague Thursday June 7, 2012 Elpidoforos S. Soteriades, MD, SM, ScD Occupational Physician

More information

Exposure Control Plan for Cytotoxic Substances

Exposure Control Plan for Cytotoxic Substances Exposure Control Plan Department of www.rms.ubc.ca UBC-RMS-OHS-ECP-17-001 Effective date: December 8, 2017 Review date: NA Supersedes: NA 1. PURPOSE Exposure Control Plan for Cytotoxic Substances The University

More information

FOR A HIGHER DEGREE OF CONFIDENCE

FOR A HIGHER DEGREE OF CONFIDENCE SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS. > Introduction Manufacturing specialized products in a pharmaceutical manufacturing environment has a specific set of requirements

More information

STANDARD OPERATING PROCEDURE #714 USE OF MPTP IN NHPS

STANDARD OPERATING PROCEDURE #714 USE OF MPTP IN NHPS STANDARD OPERATING PROCEDURE #714 USE OF MPTP IN NHPS 1. PURPOSE This Standard Operating Procedure (SOP) describes the guidelines for the use of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in

More information

Systemic Treatment of Cancer

Systemic Treatment of Cancer Systemic Treatment of Cancer Irwin H. Krakoff, MD It was demonstrated in the early 1940s that changing the hormonal milieu of certain cancers could result in their regression and that administration of

More information

The Community Oncologist

The Community Oncologist This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com The Community Oncologist Preventing Chemotherapy Errors Lisa

More information

Objectives. Principles of Cancer Treatment. Cancer Treatment Modalities. Cancer Treatment Modalities

Objectives. Principles of Cancer Treatment. Cancer Treatment Modalities. Cancer Treatment Modalities Objectives Principles of Cancer Treatment Juanita Madison, RN, MN, AOCN Oncology Clinical Nurse Specialist Seattle Cancer Care Alliance Describe the principles of cancer treatment Surgery Chemotherapy

More information

Chemotherapy: safe use of cytotoxic drugs in practice

Chemotherapy: safe use of cytotoxic drugs in practice Vet Times The website for the veterinary profession https://www.vettimes.co.uk Chemotherapy: safe use of cytotoxic drugs in practice Author : Linda Roberts Categories : RVNs Date : March 1, 2011 Linda

More information

Anticancer Drugs. Cytotoxic drugs Antineoplastic agents

Anticancer Drugs. Cytotoxic drugs Antineoplastic agents Anticancer Drugs Cytotoxic drugs Antineoplastic agents 1 Principles of Cancer Chemotherapy Cancer chemotherapy strives to cause a lethal cytotoxic event or apoptosis in the cancer cells that can arrest

More information

ZANOSAR 1g. STREPTOZOCINE Lyophilised powder for solution for injection

ZANOSAR 1g. STREPTOZOCINE Lyophilised powder for solution for injection PACKAGE LEAFLET: INFORMATION FOR THE USER ZANOSAR 1g STREPTOZOCINE Lyophilised powder for solution for injection Read all of this leaflet carefully before you start using this medicine. Keep this leaflet.

More information

Formulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class

Formulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Cancer LAST REVIEW 9/11/18 THERAPEUTIC CLASS Oncology REVIEW HISTORY 5/17, 5/16 LOB AFFECTED Medi-Cal (MONTH/YEAR) This policy

More information

Understanding Drug Therapy and Managing Side Effects

Understanding Drug Therapy and Managing Side Effects Understanding Drug Therapy and Managing Side Effects Printing of this publication made possible by an education grant from Table of Contents Introduction 1 Part 1: How Drug Therapies Work 2 Part 2: Drug

More information

Emergency Telephone (800) Mitoxantrone Injection, USP (Concentrate) Mitoxantrone Hydrochloride Antineoplastic

Emergency Telephone (800) Mitoxantrone Injection, USP (Concentrate) Mitoxantrone Hydrochloride Antineoplastic MATERIAL SAFETY DATA SHEET SECTION 1 - PRODUCT & COMPANY IDENTIFICATION 1501 East Woodfield Road Suite 300 East Schaumburg, IL 60173 (847) 969-2700 Product Identifier: Chemical Name: Category: Emergency

More information

*Combination therapy: *Cancer drugs are divided into groups: I) DNA binding agents (Intercalating and Alkylating agents) 2 types: Doxorubicin

*Combination therapy: *Cancer drugs are divided into groups: I) DNA binding agents (Intercalating and Alkylating agents) 2 types: Doxorubicin *Combination therapy: - Cancer is heterogeneous, and resistant anticancer drugs are common, so combination of drugs together is needed in order to attack cancer. *Cancer drugs are divided into groups:

More information

Melanoma. compendia. Associated ICD-9-CM Codes: Drug & Administration

Melanoma. compendia. Associated ICD-9-CM Codes: Drug & Administration Drug & Administration compendia Treatment of Melanoma With each publication, ManagedCare Oncology s Drug & Administration Compendia highlights a single medication or a group of medications that could be

More information

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For

More information

1. Purpose Documentation Description.1 4. References 8 5. Cross-References.8 6. Development of the guideline.8

1. Purpose Documentation Description.1 4. References 8 5. Cross-References.8 6. Development of the guideline.8 CLINICAL GUIDELINE For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: Oncology/Haematology Unit (excluding Paediatrics) Oncologists, Haematologists,

More information

Material Safety Data Sheet CISPLATIN INJECTION SECTION 2 COMPOSITION, INFORMATION ON INGREDIENTS

Material Safety Data Sheet CISPLATIN INJECTION SECTION 2 COMPOSITION, INFORMATION ON INGREDIENTS Material Safety Data Sheet CISPLATIN INJECTION SECTION 1 - PRODUCT MSDS NAME: Cisplatin Injection, BP SYNONYMS: Cis-Diamminedi-chloroplatinum (II) SECTION 2 COMPOSITION, INFORMATION ON INGREDIENTS Active:

More information

SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS

SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS Manufacturing specialized products in a pharmaceutical

More information

through the cell cycle. However, how we administer drugs also depends on the combinations that we give and the doses that we give.

through the cell cycle. However, how we administer drugs also depends on the combinations that we give and the doses that we give. Hello and welcome to this lecture. My name is Hillary Prescott. I am a Clinical Pharmacy Specialist at The University of Texas MD Anderson Cancer Center. My colleague, Jeff Bryan and I have prepared this

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET 300 Northfield Road Bedford, OH 44146 Telephone: (440) 232-3320 -or- (800) 562-4797 MATERIAL SAFETY DATA SHEET Section I - IDENTITY Common/Trade Name: Methotrexate Injection, USP (25 mg/ml; 2mL, 4mL, 8mL

More information

Material Safety data sheet

Material Safety data sheet EMERGENCY OVERVIEW Azathioprine Tablets, USP contains Azathioprine and excipients generally considered to be nontoxic and non-hazardous in small quantities and under conditions of normal occupational exposure.

More information

METHOTREXATE CLINICAL PRACTICE GUIDELINES FOR STAFF

METHOTREXATE CLINICAL PRACTICE GUIDELINES FOR STAFF Mary Pack Arthritis Program METHOTREXATE CLINICAL PRACTICE GUIDELINES FOR STAFF Handling of premixed injectable Methotrexate (MTX) by employees who are pregnant, breast-feeding or attempting to reproduce

More information

FIELD GUIDE AND DRUG LIST

FIELD GUIDE AND DRUG LIST FIELD GUIDE AND DRUG LIST CONTINENTAL CARE INSURANCE Continental Life Insurance Company of Brentwood, Tennessee (CLI) An Aetna Company CLICC01414 090712 FIELD GUIDE Always take enough time with every applicant

More information

Material Safety Data Sheet. Mitomycin for Injection

Material Safety Data Sheet. Mitomycin for Injection Material Safety Data Sheet Mitomycin for Injection SECTION 1 - PRODUCT MSDS ME: Mitomycin for Injection SYNONYMS: mitomycin-c SECTION 2 COMPOSITION, INFORMATION ON INGREDIENTS ACTIVE: Mitomycin ICTIVE:

More information

AMBULANCE DECONTAMINATION GUIDELINES SUSPECTED INFLUENZA PATIENT

AMBULANCE DECONTAMINATION GUIDELINES SUSPECTED INFLUENZA PATIENT AMBULANCE DECONTAMINATION GUIDELINES SUSPECTED INFLUENZA PATIENT Reprinted with the Permission of John Hill, President Iowa EMS Association Following are general guidelines for cleaning or maintaining

More information

COST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!

COST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!! UICCEMLCostingScenarios BackoftheEnvelope Calculations PreparedforWorkingGroupSession:19621November2014,Geneva MethodsSummary We have chosen a conservative approach, calculating cost per vial. We have

More information

The problem. The treatment. Special situations. Brief background on HBV Definitions of HBV reactivation. The role and timing of antiviral therapy

The problem. The treatment. Special situations. Brief background on HBV Definitions of HBV reactivation. The role and timing of antiviral therapy Pr Raymond Sayegh The problem Brief background on HBV Definitions of HBV reactivation The treatment The role and timing of antiviral therapy Special situations Lone anti-hbcpositive, rituximab, BMT, reactivation

More information

ANTI CANCER DRUGS. Dr. Datten Bangun MSc,SpFK. Dept. Farmakologi dan Terapeutik, Fakultas Kedokteran Universitas HKBP Nomensen

ANTI CANCER DRUGS. Dr. Datten Bangun MSc,SpFK. Dept. Farmakologi dan Terapeutik, Fakultas Kedokteran Universitas HKBP Nomensen ANTI CANCER DRUGS Dr. Datten Bangun MSc,SpFK Dept. Farmakologi dan Terapeutik, Fakultas Kedokteran Universitas HKBP Nomensen SITOSTATIKA CYTOSTATICS INTRODUCTION : Cyto : Cells Static : statis Synonim

More information

Pharmacology. Cell cycle

Pharmacology. Cell cycle Objectives: To define chemotherapy To define the common classes of drugs used and mechanism of action To identify dermatologic side effects of chemotherapeutic drugs Chemotherapy Definition: the treatment

More information

Symptom Management. Fertility and You

Symptom Management. Fertility and You Symptom Management Fertility and You Table of Contents 3 Will cancer impact my ability to have children? 4 How do I talk to my children about preserving their fertility during cancer treatment? 5 What

More information

This PDF is available for free download from a site hosted by Medknow Publications

This PDF is available for free download from a site hosted by Medknow Publications Review Article Cytotoxic drug: Towards safer chemotherapy practices Joshi MC Clinical Pharmacologist, Prescription Audit Department, Indraprastha Apollo Hospital, Delhi Mathura Road, Sarita Vihar, New

More information

Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data

Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: CIBMTR Research ID: Event date: / / Visit 100 day 6 months 1 year 2 years

More information

MASCC Guidelines for Antiemetic control: An update

MASCC Guidelines for Antiemetic control: An update MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,

More information

British Columbia Cancer Agency

British Columbia Cancer Agency Page 1 of 12 A. SCOPE This Policy covers the preparation, administration, and disposal of hazardous drugs. See Cancer Drug Manual Appendix 5 for the Hazardous Drug List. (www.bccancer.bc.ca/hpi/drugdatabase/appendices)

More information

Emetogenicity level 1. Emetogenicity level 2

Emetogenicity level 1. Emetogenicity level 2 Emetogenicity level 1 15 mins Pre-Chemo Maxalon 10mg po During chemo and Post Chemo 3 days Maxalon10mg po 8 hourly Increase Maxalon 20mg po 8 hourly Change to Cyclizine 50mg po 8 hourly 3 days If nausea

More information

1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.

1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation. Alberta Regulation 18/2005 Cancer Programs Act AMENDMENT REGULATION Filed: February 22, 2005 For information only: Made by the Minister of Health and Wellness (M.O. 9/2005) on February 17, 2005 pursuant

More information

DBL DACARBAZINE FOR INJECTION

DBL DACARBAZINE FOR INJECTION DBL DACARBAZINE FOR INJECTION NAME OF MEDICINE Dacarbazine The molecular formula of dacarbazine is C 6 H 10 N 6 O. Its molecular weight is 182.2. The CAS Registry number of dacarbazine is 4342-03-4. The

More information

Chapter 12. Preventing Infection. Elsevier items and derived items 2014, 2010 by Mosby, an imprint of Elsevier Inc. All rights reserved.

Chapter 12. Preventing Infection. Elsevier items and derived items 2014, 2010 by Mosby, an imprint of Elsevier Inc. All rights reserved. Chapter 12 Preventing Infection Infection Infection is a major safety and health hazard. The health team follows certain practices and procedures to protect patients, residents, visitors, and staff from

More information

Routine monitoring requirements for your mcrpc patients on Xofigo

Routine monitoring requirements for your mcrpc patients on Xofigo XOFIGO IS INDICATED for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Introduce Xofigo at the first sign

More information

A PRACTICAL GUIDE TO FELINE CANCER FOR THE CARING CAT OWNER

A PRACTICAL GUIDE TO FELINE CANCER FOR THE CARING CAT OWNER A PRACTICAL GUIDE TO FELINE CANCER FOR THE CARING CAT OWNER by Dr. Martha S. Gearhart DVM, Diplomate American Board of Veterinary Practitioners PART II: CANCER CHEMOTHERAPY In Part I of this article, the

More information

Oncology Skills Checklist

Oncology Skills Checklist Oncology Skills Checklist This assessment is for determining your experience in the below outlined clinical areas. This checklist will not be used as a determining factor in accepting your application

More information

Guidelines for the Use of Anti-Emetics with Chemotherapy

Guidelines for the Use of Anti-Emetics with Chemotherapy Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting

More information

300 Northfield Road. Telephone: (440) or- (800) Section I - IDENTITY

300 Northfield Road. Telephone: (440) or- (800) Section I - IDENTITY 300 Northfield Road Bedford, OH 44146 Telephone: (440) 232-3320 -or- (800) 562-4797 MATERIAL SAFETY DATA SHEET Section I - IDENTITY Common/Trade Name: Carboplatin 10 mg/ml; 5, 15, 45 and 60 ml vials Chemical

More information

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,

More information

CANCER CHEMOTHERAPY Michael Lea

CANCER CHEMOTHERAPY Michael Lea CANCER CHEMOTHERAPY 2010 Michael Lea Cancer Chemotherapy - Lecture Outline 1. Targets for cancer chemotherapy 2. Classification of anticancer drugs 3. Cell cycle specificity 4. Drug resistance 5. New approaches

More information

FEC: Fluorouracil, Epirubicin and Cyclophosphamide

FEC: Fluorouracil, Epirubicin and Cyclophosphamide PATIENT EDUCATION patienteducation.osumc.edu FEC: Fluorouracil, Epirubicin and Cyclophosphamide What is FEC? This is the short name for the drugs used for this chemotherapy treatment. The three drugs you

More information

Chapter 11 PREVENTING INFECTION. Elsevier items and derived items 2010 by Mosby, Inc. an affiliate of Elsevier Inc. All rights reserved

Chapter 11 PREVENTING INFECTION. Elsevier items and derived items 2010 by Mosby, Inc. an affiliate of Elsevier Inc. All rights reserved Chapter 11 PREVENTING INFECTION Infection is a major safety and health hazard. The health team follows certain practices and procedures to protect patients, residents, visitors, and staff from infection.

More information

Chapter 13. Preventing Infection. Copyright 2019 by Elsevier, Inc. All rights reserved.

Chapter 13. Preventing Infection. Copyright 2019 by Elsevier, Inc. All rights reserved. Chapter 13 Preventing Infection Copyright 2019 by Elsevier, Inc. All rights reserved. Lesson 13.1 Define the key terms and key abbreviations in this chapter. Identify what microbes need to live and grow.

More information

Hazardous Drug Safety

Hazardous Drug Safety Annual Compliance Education This course contains annual compliance education necessary to meet compliance and regulatory requirements. Instructions: To receive credit for completion: 1. Read the content

More information

Bloodborne Pathogens, Title 29 Code of Federal Regulations (CFR) Part

Bloodborne Pathogens, Title 29 Code of Federal Regulations (CFR) Part STANDARDS Bloodborne Pathogens, Title 29 Code of Federal Regulations (CFR) Part 1910.1030 1.0 PROCEDURE The Illinois Wesleyan University Physical Plant is committed to providing a safe and healthful work

More information

Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION

Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC

More information

2. Date of most recent breast cancer diagnosis / / 3. Pathlogy: Padget s Phyllodes Tubular Medullary Mucinous

2. Date of most recent breast cancer diagnosis / / 3. Pathlogy: Padget s Phyllodes Tubular Medullary Mucinous Breast Cancer Patients: Begin on page 1, then skip to page 3 Lymphoma Patients: Begin on page 2 1. Newly diagnosed with Breast carcinoma Stage: (includes inflammatory breast and newly diagnosed recurrent

More information

CHAPTER 7 Medical/Surgical Asepsis and Infection Control

CHAPTER 7 Medical/Surgical Asepsis and Infection Control CHAPTER 7 Medical/Surgical Asepsis and Infection Control 1 Slide 1 Microorganisms Microscopic. Naturally present on and in the human body and environment. Some microorganisms (pathogens) cause specific

More information

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA

More information

Form 2023 R2.0: Ovarian Cancer Pre-HSCT Data

Form 2023 R2.0: Ovarian Cancer Pre-HSCT Data Key Fields Sequence Number Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous

More information

Routine monitoring requirements for your mcrpc patients on Xofigo

Routine monitoring requirements for your mcrpc patients on Xofigo XOFIGO IS INDICATED for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Introduce Xofigo at the first sign

More information

MEDICAL NECESSITY GUIDELINE

MEDICAL NECESSITY GUIDELINE PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information